EVAN MORRIS

S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals Act"; proposed cuts to Part B reimbursement. 340b reimbursement policy; MMM: Part B reimbursement; HCR: Issues related to the implementation of the Affordable Care Act of 2010, HCR: Issues relating to the treatment of biologics in international health programs, Reimbursement issues, Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicar drug benefit.; Issues relate to the 340B Drug discount program; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act";Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis; Issues relating to biologics

S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals; Medical Countermeasure Stockpile 340B Drug Discounting Program; FOR - Issues related to the treatment of biologics in international health programs specifically under the Pan American Health Organization

S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals Act"; proposed cuts to Part B reimbursement. 340b reimbursement policy; MMM: Part B reimbursement; HCR: Issues related to the implementation of the Affordable Care Act of 2010, HCR: Issues relating to the treatment of biologics in international health programs, Reimbursement issues, Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicar drug benefit.; Issues relate to the 340B Drug discount program; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act";Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis; Issues relating to biologics

Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics; Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit; Regulatory and legislative activities regarding 340B program; Issues relating to biologics; S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals Act"; Issues related to the implementation of the Affordable Care Act of 2010; issues related to biosimilars; Issues concerning clinical trials; issues concerning drug compounding. Implementation of Patient Protection and Affordable Care Act. Federal Drug. Drug pricing under 340B program; Medical reimbursement - advocacy on behalf of maintaining ASP+6%, 340B Drug Discounting Program - education of Congress on unintended growth of program; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act"; PHA: Monitor Drug Safety and pedigree legislation. Monitor legislation and oversight on compounding pharmacies.

S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals Act"; proposed cuts to Part B reimbursement. 340b reimbursement policy; MMM: Part B reimbursement; HCR: Issues related to the implementation of the Affordable Care Act of 2010, HCR: Issues relating to the treatment of biologics in international health programs, Reimbursement issues, Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicar drug benefit.; Issues relate to the 340B Drug discount program; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act";Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis; Issues relating to biologics

S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals; Medical Countermeasure Stockpile 340B Drug Discounting Program; FOR - Issues related to the treatment of biologics in international health programs specifically under the Pan American Health Organization

Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement, Public Law 11-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cance biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government ofr fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Acto f 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimbursement issues. Concerns regarding Medicare payment policies for Part B drugs. HCR: Issues relate to the 340B Drug discount program; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act"; PHA: Monitor Drug Safety and pedigree legislation. Monitor legislation and oversight on compounding pharmacies.Implementation of P.L. 108-173, matters related to Medi care and Medicaid Coverage and Reimbursement (Medicare Prescription Drug Act of 2003); issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; HR 942 - American Research and Competitiveness Act of 2011; Issues related to 340B; Medicare coverage and payment of Part B drugs and bilogicals.

Concerns regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program, Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement (Medicare Prescription Drug savings and Choice Act of 2013, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 928/h>r. 1102); issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; HR 4438 - American Research and Competitiveness Act of 2014; Issues related to 340, Medicare coverage and payment of Part B drugs and bilogicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eldgible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Acto f 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues

Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Act of 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues.spending. Public law 113-54- The Drug quality and Security Act - drug compounding and track trace issues.; Concerns regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program; Payment policies for prescription drugs. Independent payment advisory board, H.R.2810, Medicare Patient Access and Quality Improvement Act of 2013; Medicare reimbursement issues; Medicare coverage and payment of Part B drugs and biologicals; 340B, Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligiable demonstratins and relaed provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act;

Concerns regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program, Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement (Medicare Prescription Drug savings and Choice Act of 2013, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 928/h>r. 1102); issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; HR 4438 - American Research and Competitiveness Act of 2014; Issues related to 340, Medicare coverage and payment of Part B drugs and bilogicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eldgible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Acto f 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues

Medicare coverage and payment of Part B drugs and bilogicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligiable demonstratins and relaed provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Act of 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicare Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues.

Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement, Public Law 11-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cance biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government ofr fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Acto f 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimbursement issues. Concerns regarding Medicare payment policies for Part B drugs. HCR: Issues relate to the 340B Drug discount program; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act"; PHA: Monitor Drug Safety and pedigree legislation. Monitor legislation and oversight on compounding pharmacies.Implementation of P.L. 108-173, matters related to Medi care and Medicaid Coverage and Reimbursement (Medicare Prescription Drug Act of 2003); issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; HR 942 - American Research and Competitiveness Act of 2011; Issues related to 340B; Medicare coverage and payment of Part B drugs and bilogicals.

Concerns regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program, Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement (Medicare Prescription Drug savings and Choice Act of 2013, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 928/h>r. 1102); issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; HR 4438 - American Research and Competitiveness Act of 2014; Issues related to 340, Medicare coverage and payment of Part B drugs and bilogicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eldgible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Acto f 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues

Concerns regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program, Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement (Medicare Prescription Drug savings and Choice Act of 2013, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 928/h>r. 1102); issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; HR 4438 - American Research and Competitiveness Act of 2014; Issues related to 340, Medicare coverage and payment of Part B drugs and bilogicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eldgible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Acto f 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues

Concerns regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program, Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement (Medicare Prescription Drug savings and Choice Act of 2013, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 928/h>r. 1102); issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; HR 4438 - American Research and Competitiveness Act of 2014; Issues related to 340, Medicare coverage and payment of Part B drugs and bilogicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eldgible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Acto f 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues

Concerns regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program, Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement (Medicare Prescription Drug savings and Choice Act of 2013, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 928/h>r. 1102); issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; HR 4438 - American Research and Competitiveness Act of 2014; Issues related to 340, Medicare coverage and payment of Part B drugs and bilogicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eldgible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Acto f 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues

Concerns regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program, Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement (Medicare Prescription Drug savings and Choice Act of 2013, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 928/h>r. 1102); issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; HR 4438 - American Research and Competitiveness Act of 2014; Issues related to 340, Medicare coverage and payment of Part B drugs and bilogicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eldgible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Acto f 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues

Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Act of 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues.spending. Public law 113-54- The Drug quality and Security Act - drug compounding and track trace issues.; Concerns regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program; Payment policies for prescription drugs. Independent payment advisory board, H.R.2810, Medicare Patient Access and Quality Improvement Act of 2013; Medicare reimbursement issues; Medicare coverage and payment of Part B drugs and biologicals; 340B, Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligiable demonstratins and relaed provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act;

Concerns regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program, Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement (Medicare Prescription Drug savings and Choice Act of 2013, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 928/h>r. 1102); issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; HR 4438 - American Research and Competitiveness Act of 2014; Issues related to 340, Medicare coverage and payment of Part B drugs and bilogicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eldgible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Acto f 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues

Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement, Public Law 11-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cance biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government ofr fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Acto f 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimbursement issues. Concerns regarding Medicare payment policies for Part B drugs. HCR: Issues relate to the 340B Drug discount program; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act"; PHA: Monitor Drug Safety and pedigree legislation. Monitor legislation and oversight on compounding pharmacies.Implementation of P.L. 108-173, matters related to Medi care and Medicaid Coverage and Reimbursement (Medicare Prescription Drug Act of 2003); issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; HR 942 - American Research and Competitiveness Act of 2011; Issues related to 340B; Medicare coverage and payment of Part B drugs and bilogicals.

Medicare coverage and payment of Part B drugs and bilogicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligiable demonstratins and relaed provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Act of 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicare Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues.

Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement, Public Law 11-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cance biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government ofr fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Acto f 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimbursement issues. Concerns regarding Medicare payment policies for Part B drugs. HCR: Issues relate to the 340B Drug discount program; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act"; PHA: Monitor Drug Safety and pedigree legislation. Monitor legislation and oversight on compounding pharmacies.Implementation of P.L. 108-173, matters related to Medi care and Medicaid Coverage and Reimbursement (Medicare Prescription Drug Act of 2003); issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; HR 942 - American Research and Competitiveness Act of 2011; Issues related to 340B; Medicare coverage and payment of Part B drugs and bilogicals.

Medicare coverage and payment of Part B drugs and bilogicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligiable demonstratins and relaed provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Act of 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicare Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues.

Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Act of 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues.spending. Public law 113-54- The Drug quality and Security Act - drug compounding and track trace issues.; Concerns regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program; Payment policies for prescription drugs. Independent payment advisory board, H.R.2810, Medicare Patient Access and Quality Improvement Act of 2013; Medicare reimbursement issues; Medicare coverage and payment of Part B drugs and biologicals; 340B, Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligiable demonstratins and relaed provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act;

Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement, Public Law 11-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cance biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government ofr fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Acto f 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimbursement issues. Concerns regarding Medicare payment policies for Part B drugs. HCR: Issues relate to the 340B Drug discount program; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act"; PHA: Monitor Drug Safety and pedigree legislation. Monitor legislation and oversight on compounding pharmacies.Implementation of P.L. 108-173, matters related to Medi care and Medicaid Coverage and Reimbursement (Medicare Prescription Drug Act of 2003); issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; HR 942 - American Research and Competitiveness Act of 2011; Issues related to 340B; Medicare coverage and payment of Part B drugs and bilogicals.

Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement, Public Law 11-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cance biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government ofr fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Acto f 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimbursement issues. Concerns regarding Medicare payment policies for Part B drugs. HCR: Issues relate to the 340B Drug discount program; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act"; PHA: Monitor Drug Safety and pedigree legislation. Monitor legislation and oversight on compounding pharmacies.Implementation of P.L. 108-173, matters related to Medi care and Medicaid Coverage and Reimbursement (Medicare Prescription Drug Act of 2003); issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; HR 942 - American Research and Competitiveness Act of 2011; Issues related to 340B; Medicare coverage and payment of Part B drugs and bilogicals.

Concerns regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program, Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement (Medicare Prescription Drug savings and Choice Act of 2013, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 928/h>r. 1102); issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; HR 4438 - American Research and Competitiveness Act of 2014; Issues related to 340, Medicare coverage and payment of Part B drugs and bilogicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eldgible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Acto f 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues

Concerns regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program, Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement (Medicare Prescription Drug savings and Choice Act of 2013, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 928/h>r. 1102); issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; HR 4438 - American Research and Competitiveness Act of 2014; Issues related to 340, Medicare coverage and payment of Part B drugs and bilogicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eldgible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Acto f 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues

Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics; Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit; Regulatory and legislative activities regarding 340B program; Issues relating to biologics; S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals Act"; Issues related to the implementation of the Affordable Care Act of 2010; issues related to biosimilars; Issues concerning clinical trials; issues concerning drug compounding. Implementation of Patient Protection and Affordable Care Act. Federal Drug. Drug pricing under 340B program; Medical reimbursement - advocacy on behalf of maintaining ASP+6%, 340B Drug Discounting Program - education of Congress on unintended growth of program; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act"; PHA: Monitor Drug Safety and pedigree legislation. Monitor legislation and oversight on compounding pharmacies.

S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals; Medical Countermeasure Stockpile 340B Drug Discounting Program; FOR - Issues related to the treatment of biologics in international health programs specifically under the Pan American Health Organization

S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals Act"; proposed cuts to Part B reimbursement. 340b reimbursement policy; MMM: Part B reimbursement; HCR: Issues related to the implementation of the Affordable Care Act of 2010, HCR: Issues relating to the treatment of biologics in international health programs, Reimbursement issues, Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicar drug benefit.; Issues relate to the 340B Drug discount program; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act";Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis; Issues relating to biologics

S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals Act"; proposed cuts to Part B reimbursement. 340b reimbursement policy; MMM: Part B reimbursement; HCR: Issues related to the implementation of the Affordable Care Act of 2010, HCR: Issues relating to the treatment of biologics in international health programs, Reimbursement issues, Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicar drug benefit.; Issues relate to the 340B Drug discount program; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act";Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis; Issues relating to biologics

S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals; Medical Countermeasure Stockpile 340B Drug Discounting Program; FOR - Issues related to the treatment of biologics in international health programs specifically under the Pan American Health Organization

S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals Act"; proposed cuts to Part B reimbursement. 340b reimbursement policy; MMM: Part B reimbursement; HCR: Issues related to the implementation of the Affordable Care Act of 2010, HCR: Issues relating to the treatment of biologics in international health programs, Reimbursement issues, Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicar drug benefit.; Issues relate to the 340B Drug discount program; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act";Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis; Issues relating to biologics

S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals Act"; proposed cuts to Part B reimbursement. 340b reimbursement policy; MMM: Part B reimbursement; HCR: Issues related to the implementation of the Affordable Care Act of 2010, HCR: Issues relating to the treatment of biologics in international health programs, Reimbursement issues, Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicar drug benefit.; Issues relate to the 340B Drug discount program; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act";Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis; Issues relating to biologics

Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics; Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit; Regulatory and legislative activities regarding 340B program; Issues relating to biologics; S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals Act"; Issues related to the implementation of the Affordable Care Act of 2010; issues related to biosimilars; Issues concerning clinical trials; issues concerning drug compounding. Implementation of Patient Protection and Affordable Care Act. Federal Drug. Drug pricing under 340B program; Medical reimbursement - advocacy on behalf of maintaining ASP+6%, 340B Drug Discounting Program - education of Congress on unintended growth of program; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act"; PHA: Monitor Drug Safety and pedigree legislation. Monitor legislation and oversight on compounding pharmacies.

Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement, Public Law 11-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cance biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government ofr fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Acto f 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimbursement issues. Concerns regarding Medicare payment policies for Part B drugs. HCR: Issues relate to the 340B Drug discount program; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act"; PHA: Monitor Drug Safety and pedigree legislation. Monitor legislation and oversight on compounding pharmacies.Implementation of P.L. 108-173, matters related to Medi care and Medicaid Coverage and Reimbursement (Medicare Prescription Drug Act of 2003); issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; HR 942 - American Research and Competitiveness Act of 2011; Issues related to 340B; Medicare coverage and payment of Part B drugs and bilogicals.

Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement, Public Law 11-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cance biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government ofr fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Acto f 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimbursement issues. Concerns regarding Medicare payment policies for Part B drugs. HCR: Issues relate to the 340B Drug discount program; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act"; PHA: Monitor Drug Safety and pedigree legislation. Monitor legislation and oversight on compounding pharmacies.Implementation of P.L. 108-173, matters related to Medi care and Medicaid Coverage and Reimbursement (Medicare Prescription Drug Act of 2003); issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; HR 942 - American Research and Competitiveness Act of 2011; Issues related to 340B; Medicare coverage and payment of Part B drugs and bilogicals.

Concerns regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program, Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement (Medicare Prescription Drug savings and Choice Act of 2013, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 928/h>r. 1102); issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; HR 4438 - American Research and Competitiveness Act of 2014; Issues related to 340, Medicare coverage and payment of Part B drugs and bilogicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eldgible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Acto f 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues

Concerns regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program, Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement (Medicare Prescription Drug savings and Choice Act of 2013, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 928/h>r. 1102); issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; HR 4438 - American Research and Competitiveness Act of 2014; Issues related to 340, Medicare coverage and payment of Part B drugs and bilogicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eldgible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Acto f 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues

Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Act of 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues.spending. Public law 113-54- The Drug quality and Security Act - drug compounding and track trace issues.; Concerns regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program; Payment policies for prescription drugs. Independent payment advisory board, H.R.2810, Medicare Patient Access and Quality Improvement Act of 2013; Medicare reimbursement issues; Medicare coverage and payment of Part B drugs and biologicals; 340B, Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligiable demonstratins and relaed provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act;

Medicare coverage and payment of Part B drugs and bilogicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligiable demonstratins and relaed provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Act of 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicare Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues.

Issues relating to biologics, S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals Act, proposed cuts to Part B reimbursement. 340b reimbursement policy, Issues related to the treatment of biologics in international health programs, Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit.; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis.

Issues relating to biologics, S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals Act, proposed cuts to Part B reimbursement. 340b reimbursement policy, Issues related to the treatment of biologics in international health programs, Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit.; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis.

Issues relating to biologics, S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals Act, proposed cuts to Part B reimbursement. 340b reimbursement policy, Issues related to the treatment of biologics in international health programs, Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit.; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis.

Issues relating to biologics, S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals Act, proposed cuts to Part B reimbursement. 340b reimbursement policy, Issues related to the treatment of biologics in international health programs, Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit.; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis.

Issues relating to biologics, S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals Act, proposed cuts to Part B reimbursement. 340b reimbursement policy, Issues related to the treatment of biologics in international health programs, Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit.; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis.

Issues relating to biologics, S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals Act, proposed cuts to Part B reimbursement. 340b reimbursement policy, Issues related to the treatment of biologics in international health programs, Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit.; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis.

Issues relating to biologics, S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals Act, proposed cuts to Part B reimbursement. 340b reimbursement policy, Issues related to the treatment of biologics in international health programs, Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit.; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis.

Issues relating to biologics, S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals Act, proposed cuts to Part B reimbursement. 340b reimbursement policy, Issues related to the treatment of biologics in international health programs, Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit.; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis.

Issues relating to the treatment of biologics in international health programs; proposed cuts to Part B reimbursement. 340b reimbursement policy; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis.; Issues concerning trials; issues concerning drug compounding. Implementation of Patient Protection and Affordable Care Act; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act"; S.959, Pharmaceutical Compounding Quality and Accountability Act; H.R. 1416, Cancer Patient Protection Act of 2013; S. 957, Drug Supply Chain Security Act; H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013; Pandemic preparedness, Tamiflu, Medicare coverage of Cancer Drugs, Appropriations; implementation of section 340B of the Public Health Service Act (42 U.S.C. 256b); Issues relating to the treatment of biologics in international health programs

Pandemic preparedness, Tamiflu, Medicare coverage of Cancer Drugs, Appropriations.; S.959, Pharmaceutical Compounding Quality and Accountability Act; H.R. 1416, Cancer Patient Protection Act of 2013; S. 957, Drug Supply Chain Security Act; H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013; compounding issues; FY 13 Labor HHS Appropriations legislation; issues related to FDA user fee reauthorization; H.R. 942 S. 1577; S. 3187; Pedigree and biologics issues; H.R. 905: ASP issues; H.R. 5651; issues concerning drug compounding. Implementation of Patient Protection and Affordable Care Act; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis; implementation of section 340B of the Public Health Service Act (42 U.S.C. 256b); Implementation of H.R. 1: Medicare Prescription Drug and Modernization Act of 2003; Issues relating to PDUFA stimulus. Avastin-use in breast cancer treatment: general patient reform isse: implementation of the Affordable Care Act of 2010; Issues relating to the treatment of biologics in international health programs.

Reimbursement issues; Issues relating to the treatment of biologics in international health programs; Issues related to the implementation of the Affordable Care Act of 2010; proposed cuts to Part B reimbursement. 340b reimbursement policy; Implementation of H.R. S. 959, "Pharmaceutical Compounding Quality and Accounting Act", H.R 1416, "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", H.R. 1919, "Safeguarding America's Pharmaceuticals Act"

Reimbursement issues; Issues relating to the treatment of biologics in international health programs; Issues related to the implementation of the Affordable Care Act of 2010; proposed cuts to Part B reimbursement. 340b reimbursement policy; Implementation of H.R. S. 959, "Pharmaceutical Compounding Quality and Accounting Act", H.R 1416, "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", H.R. 1919, "Safeguarding America's Pharmaceuticals Act"

Pandemic preparedness, Tamiflu, Medicare coverage of Cancer Drugs, Appropriations.; S.959, Pharmaceutical Compounding Quality and Accountability Act; H.R. 1416, Cancer Patient Protection Act of 2013; S. 957, Drug Supply Chain Security Act; H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013; compounding issues; FY 13 Labor HHS Appropriations legislation; issues related to FDA user fee reauthorization; H.R. 942 S. 1577; S. 3187; Pedigree and biologics issues; H.R. 905: ASP issues; H.R. 5651; issues concerning drug compounding. Implementation of Patient Protection and Affordable Care Act; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis; implementation of section 340B of the Public Health Service Act (42 U.S.C. 256b); Implementation of H.R. 1: Medicare Prescription Drug and Modernization Act of 2003; Issues relating to PDUFA stimulus. Avastin-use in breast cancer treatment: general patient reform isse: implementation of the Affordable Care Act of 2010; Issues relating to the treatment of biologics in international health programs.

Issues relating to the treatment of biologics in international health programs; proposed cuts to Part B reimbursement. 340b reimbursement policy; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis.; Issues concerning trials; issues concerning drug compounding. Implementation of Patient Protection and Affordable Care Act; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act"; S.959, Pharmaceutical Compounding Quality and Accountability Act; H.R. 1416, Cancer Patient Protection Act of 2013; S. 957, Drug Supply Chain Security Act; H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013; Pandemic preparedness, Tamiflu, Medicare coverage of Cancer Drugs, Appropriations; implementation of section 340B of the Public Health Service Act (42 U.S.C. 256b); Issues relating to the treatment of biologics in international health programs

Issues related to FDA & HHS program funding, FY14 Labor Health and Human Services, and Education, and Related Agenciesand H.R 2410, FY14 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Bills.; FY13 Labor, HHS and Education Appropriation related to preparedness for pandemic influenca, HIV/AIDS programs, hepatitis screening, care and treatment, and access to breast cancer treatment.

Pandemic preparedness, Tamiflu, Medicare coverage of Cancer Drugs, Appropriations.; S.959, Pharmaceutical Compounding Quality and Accountability Act; H.R. 1416, Cancer Patient Protection Act of 2013; S. 957, Drug Supply Chain Security Act; H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013; compounding issues; FY 13 Labor HHS Appropriations legislation; issues related to FDA user fee reauthorization; H.R. 942 S. 1577; S. 3187; Pedigree and biologics issues; H.R. 905: ASP issues; H.R. 5651; issues concerning drug compounding. Implementation of Patient Protection and Affordable Care Act; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis; implementation of section 340B of the Public Health Service Act (42 U.S.C. 256b); Implementation of H.R. 1: Medicare Prescription Drug and Modernization Act of 2003; Issues relating to PDUFA stimulus. Avastin-use in breast cancer treatment: general patient reform isse: implementation of the Affordable Care Act of 2010; Issues relating to the treatment of biologics in international health programs.

Pandemic preparedness, Tamiflu, Medicare coverage of Cancer Drugs, Appropriations.; S.959, Pharmaceutical Compounding Quality and Accountability Act; H.R. 1416, Cancer Patient Protection Act of 2013; S. 957, Drug Supply Chain Security Act; H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013; compounding issues; FY 13 Labor HHS Appropriations legislation; issues related to FDA user fee reauthorization; H.R. 942 S. 1577; S. 3187; Pedigree and biologics issues; H.R. 905: ASP issues; H.R. 5651; issues concerning drug compounding. Implementation of Patient Protection and Affordable Care Act; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis; implementation of section 340B of the Public Health Service Act (42 U.S.C. 256b); Implementation of H.R. 1: Medicare Prescription Drug and Modernization Act of 2003; Issues relating to PDUFA stimulus. Avastin-use in breast cancer treatment: general patient reform isse: implementation of the Affordable Care Act of 2010; Issues relating to the treatment of biologics in international health programs.

Pandemic preparedness, Tamiflu, Medicare coverage of Cancer Drugs, Appropriations.; S.959, Pharmaceutical Compounding Quality and Accountability Act; H.R. 1416, Cancer Patient Protection Act of 2013; S. 957, Drug Supply Chain Security Act; H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013; compounding issues; FY 13 Labor HHS Appropriations legislation; issues related to FDA user fee reauthorization; H.R. 942 S. 1577; S. 3187; Pedigree and biologics issues; H.R. 905: ASP issues; H.R. 5651; issues concerning drug compounding. Implementation of Patient Protection and Affordable Care Act; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis; implementation of section 340B of the Public Health Service Act (42 U.S.C. 256b); Implementation of H.R. 1: Medicare Prescription Drug and Modernization Act of 2003; Issues relating to PDUFA stimulus. Avastin-use in breast cancer treatment: general patient reform isse: implementation of the Affordable Care Act of 2010; Issues relating to the treatment of biologics in international health programs.

Pandemic preparedness, Tamiflu, Medicare coverage of Cancer Drugs, Appropriations.; S.959, Pharmaceutical Compounding Quality and Accountability Act; H.R. 1416, Cancer Patient Protection Act of 2013; S. 957, Drug Supply Chain Security Act; H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013; compounding issues; FY 13 Labor HHS Appropriations legislation; issues related to FDA user fee reauthorization; H.R. 942 S. 1577; S. 3187; Pedigree and biologics issues; H.R. 905: ASP issues; H.R. 5651; issues concerning drug compounding. Implementation of Patient Protection and Affordable Care Act; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis; implementation of section 340B of the Public Health Service Act (42 U.S.C. 256b); Implementation of H.R. 1: Medicare Prescription Drug and Modernization Act of 2003; Issues relating to PDUFA stimulus. Avastin-use in breast cancer treatment: general patient reform isse: implementation of the Affordable Care Act of 2010; Issues relating to the treatment of biologics in international health programs.

Issues relating to the treatment of biologics in international health programs; proposed cuts to Part B reimbursement. 340b reimbursement policy; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis.; Issues concerning trials; issues concerning drug compounding. Implementation of Patient Protection and Affordable Care Act; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act"; S.959, Pharmaceutical Compounding Quality and Accountability Act; H.R. 1416, Cancer Patient Protection Act of 2013; S. 957, Drug Supply Chain Security Act; H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013; Pandemic preparedness, Tamiflu, Medicare coverage of Cancer Drugs, Appropriations; implementation of section 340B of the Public Health Service Act (42 U.S.C. 256b); Issues relating to the treatment of biologics in international health programs

Pandemic preparedness, Tamiflu, Medicare coverage of Cancer Drugs, Appropriations.; S.959, Pharmaceutical Compounding Quality and Accountability Act; H.R. 1416, Cancer Patient Protection Act of 2013; S. 957, Drug Supply Chain Security Act; H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013; compounding issues; FY 13 Labor HHS Appropriations legislation; issues related to FDA user fee reauthorization; H.R. 942 S. 1577; S. 3187; Pedigree and biologics issues; H.R. 905: ASP issues; H.R. 5651; issues concerning drug compounding. Implementation of Patient Protection and Affordable Care Act; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis; implementation of section 340B of the Public Health Service Act (42 U.S.C. 256b); Implementation of H.R. 1: Medicare Prescription Drug and Modernization Act of 2003; Issues relating to PDUFA stimulus. Avastin-use in breast cancer treatment: general patient reform isse: implementation of the Affordable Care Act of 2010; Issues relating to the treatment of biologics in international health programs.

Reimbursement issues; Issues relating to the treatment of biologics in international health programs; Issues related to the implementation of the Affordable Care Act of 2010; proposed cuts to Part B reimbursement. 340b reimbursement policy; Implementation of H.R. S. 959, "Pharmaceutical Compounding Quality and Accounting Act", H.R 1416, "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", H.R. 1919, "Safeguarding America's Pharmaceuticals Act"

Reimbursement issues; Issues relating to the treatment of biologics in international health programs; Issues related to the implementation of the Affordable Care Act of 2010; proposed cuts to Part B reimbursement. 340b reimbursement policy; Implementation of H.R. S. 959, "Pharmaceutical Compounding Quality and Accounting Act", H.R 1416, "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", H.R. 1919, "Safeguarding America's Pharmaceuticals Act"

Issues relating to the treatment of biologics in international health programs; proposed cuts to Part B reimbursement. 340b reimbursement policy; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis.; Issues concerning trials; issues concerning drug compounding. Implementation of Patient Protection and Affordable Care Act; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act"; S.959, Pharmaceutical Compounding Quality and Accountability Act; H.R. 1416, Cancer Patient Protection Act of 2013; S. 957, Drug Supply Chain Security Act; H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013; Pandemic preparedness, Tamiflu, Medicare coverage of Cancer Drugs, Appropriations; implementation of section 340B of the Public Health Service Act (42 U.S.C. 256b); Issues relating to the treatment of biologics in international health programs

Pandemic preparedness, Tamiflu, Medicare coverage of Cancer Drugs, Appropriations.; S.959, Pharmaceutical Compounding Quality and Accountability Act; H.R. 1416, Cancer Patient Protection Act of 2013; S. 957, Drug Supply Chain Security Act; H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013; compounding issues; FY 13 Labor HHS Appropriations legislation; issues related to FDA user fee reauthorization; H.R. 942 S. 1577; S. 3187; Pedigree and biologics issues; H.R. 905: ASP issues; H.R. 5651; issues concerning drug compounding. Implementation of Patient Protection and Affordable Care Act; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis; implementation of section 340B of the Public Health Service Act (42 U.S.C. 256b); Implementation of H.R. 1: Medicare Prescription Drug and Modernization Act of 2003; Issues relating to PDUFA stimulus. Avastin-use in breast cancer treatment: general patient reform isse: implementation of the Affordable Care Act of 2010; Issues relating to the treatment of biologics in international health programs.

Pandemic preparedness, Tamiflu, Medicare coverage of Cancer Drugs, Appropriations.; S.959, Pharmaceutical Compounding Quality and Accountability Act; H.R. 1416, Cancer Patient Protection Act of 2013; S. 957, Drug Supply Chain Security Act; H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013; compounding issues; FY 13 Labor HHS Appropriations legislation; issues related to FDA user fee reauthorization; H.R. 942 S. 1577; S. 3187; Pedigree and biologics issues; H.R. 905: ASP issues; H.R. 5651; issues concerning drug compounding. Implementation of Patient Protection and Affordable Care Act; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis; implementation of section 340B of the Public Health Service Act (42 U.S.C. 256b); Implementation of H.R. 1: Medicare Prescription Drug and Modernization Act of 2003; Issues relating to PDUFA stimulus. Avastin-use in breast cancer treatment: general patient reform isse: implementation of the Affordable Care Act of 2010; Issues relating to the treatment of biologics in international health programs.

Intellectual Property and Process Patent Issues - HR 1908. Patent Reform Act (all provisions); Cyber security , implementation of S.23: American Invents Act, Implementation of HR 1249; Transpacific partnership

Implementation of H.R. 1: Medicare Prescription Drug and Modernization Act of 2003; Issues relating to PDUFA,stimulus. Issues relating to comparative effectiveness and CMS coverage of FDA approved therapties. Issues related to the PPS ruel involving stroke guidelines. Implementation of the follow-on biologice provisions in P.L. 111-148- "Patient Protection and Affordable Care Act"; legislation on public health preparedness and response related to pandemic influenza. Influenz Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis; FDA Approval and enforcement issues. Issues relating to S.3187, FDA Safety and Innovation Act. Issues relating to antibiotic development incentives in HR 2182 and S 1734, "Generating Antibiotic Incentives Now Act of 2011"; Prescription Drug User Fee Act (PDUFA) Reauthorization;Issues related to the implementationof the Affordable Care Act of 2010;

Implementation of H.R. 1; Medicare Prescription Drug and Modernization Act of 2003; Issues related to the PPPS rule involving stroke guidelines. Proposals to reduce Medicare payment for Part B biologics. Concerns regarding Medicare payment policies for Biologics; issues relating to Prescription Drug User Fee Act and SP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; H.R. 942- American Research & Competitiveness Act of 2011.; Medicare coverage and payment of Part B drugs and biologics; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eldgible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; proposed cuts to Part B reimbursement; implementation of Health reform; Legislation for CMS.

TAX Monitoring proposals on US tax treatment of foreign-owned US Corporations; general tax issues and tax extenders (R&D tax credit) and tax treatment of foreign-owned US corporations.Research and Development Tax credit, alternative sales pricing; R&D Tax Credit (H.R. 942) FDA Appropriations, PDUFA Reauthorization; Issues related to comprehensive tax reform, tax treatment of foreign-owned U.S. corporations, and tax extenders, including R & D tax credit. S.3521, Family and Business Tax Cut Certainty Act of 2012 (tax extenders). Corporate tax reform issues (no specific legislation) Implementation of healthcare reform law. FDA drug approval and appeal oversight process. Issues related to patient and physician choice in medical treatments. PDUFA reauthorization. FY13 appropriations bills, including issues related to FDA funding and drug approval/review oversight process. Legislation related to altering sequestration targets. Issues related to comprehensive tax reform, tax treatment of foreign-owned U.S. corporations, and tax extenders, including R & D tax credit. S.3521, Family and Business Tax Cut Certainty Act of 2012 (tax extenders). Corporate tax reform issues (no specific legislation)

Intellectual Property and Process Patent Issues; HR 1908, Patent Reform Act (all provisions); S.23 - Patent Reform Act; General Patent Reform Issues; Specfic issues lobbied (bill numbers): Patent reform legislation

Issues related to pandemic preparedness and macular degeneration; FY11, FY12 Labor, HHS and Education Appropriation related to preparedness for pandemic influenza, HIV/AIDS programs and HCV screening, care and treatment. Implementation of HR 2346, S.1054 FY09 Supplemental Appropriations related to preparedness for pandemic influenza.

FY11, FY12 Labor, HHS and Education Appropriation related to preparedness for pandemic influenza, HIV/AIDS programs, hepatitis screening, care and treatment, and access to breast cancer treatment. Implementation of H.R. 2346, S. 1054 FY09 Supplemental Appropriations related to preparedness for pandemic influenza.; issues related to pandemic preparedness and macular degeneration. FY11 appropriations process - including HR 1 and various Continuing Resolutions

Issues related to pandemic preparedness and macular degeneration; HCR: Issues related to health care reform; FY11 FY12 Labor, HHS and Education Appropriation related to preparedness for pandemic influenza, HIV/AIDS programs and HCV screening, care and treatment. Implementation of HR 2346, S.1054 FY09 Supplemental Appropriations related to preparedness for pandemic influenza

Patent Reform, CPT - H.R. 243 Patent Lawsuit Reform Act of 2011; H.R. 1249 Leahy-Smith America Invents Act S.23-America Invents Act.

Medicare Issues; Monitor implementation of Medicare Pharmaceutical converage and reimbursement provisions of the Affordable Care Act, Medicare coverage and payment of Part B drugs and biologicals. Support for H.R 452 "Medicare Decision Accountability Act of 2011 and S.668 "Health Care Bureaucrats Elmination Act".

Avastin, Lucentis,FDA Appropriations; Issues concerning clincial trials. General health care reform (Patient Protection and Affordable Care Act). Congressional oversight issues; Legislation on public health preparedness and response to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels; FDA approval and enforcement issues; Presciption Drug User Fee Act (PDUFA), Avastin -use in breast cancer treatment, dry macular degeneration; S.726/HR 1427 - Promoting Innovation and Access to Life-Saving Medicine Act; HR 1548 - Pathway for Biosimilars Act, General support for Genentech products; HR1/1473 health care funding: FY 12 Labor HHS Appropriations legislation

Avastin, Lucentis, FDA, Appropriations; Issues concerning clinical trias. General health care reform (Patient Protection and Affordable Care Act). Congressional oversight issues; Legislation on public health preparedness and response to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels; FDA approval and enforcement issues; Prescription Drug User Fee Act (PDUFA), Avastin - use in breast cancer treatment, macular degeneration, S.726/HR 1427 - Promoting Innovation and Access to Life-Saving Medicine Act; HR 1548 - Pathway for Biosimilars Act, General support for Genentech products; HR1/1473 health care funding : FY 12 Labor HHS Appropriations legislation.

Avastin, Lucentis,FDA Appropriations; Issues concerning clincial trials. General health care reform (Patient Protection and Affordable Care Act). Congressional oversight issues; Legislation on public health preparedness and response to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels; FDA approval and enforcement issues; Presciption Drug User Fee Act (PDUFA), Avastin -use in breast cancer treatment, dry macular degeneration; S.726/HR 1427 - Promoting Innovation and Access to Life-Saving Medicine Act; HR 1548 - Pathway for Biosimilars Act, General support for Genentech products; HR1/1473 health care funding: FY 12 Labor HHS Appropriations legislation

Avastin, Lucentis, FDA, Appropriations; Issues concerning clinical trias. General health care reform (Patient Protection and Affordable Care Act). Congressional oversight issues; Legislation on public health preparedness and response to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels; FDA approval and enforcement issues; Prescription Drug User Fee Act (PDUFA), Avastin - use in breast cancer treatment, macular degeneration, S.726/HR 1427 - Promoting Innovation and Access to Life-Saving Medicine Act; HR 1548 - Pathway for Biosimilars Act, General support for Genentech products; HR1/1473 health care funding : FY 12 Labor HHS Appropriations legislation.

Issues related to pandemic preparedness and macular degeneration; FY11, FY12 Labor, HHS and Education Appropriation related to preparedness for pandemic influenza, HIV/AIDS programs and HCV screening, care and treatment. Implementation of HR 2346, S.1054 FY09 Supplemental Appropriations related to preparedness for pandemic influenza.

FY11, FY12 Labor, HHS and Education Appropriation related to preparedness for pandemic influenza, HIV/AIDS programs, hepatitis screening, care and treatment, and access to breast cancer treatment. Implementation of H.R. 2346, S. 1054 FY09 Supplemental Appropriations related to preparedness for pandemic influenza.; issues related to pandemic preparedness and macular degeneration. FY11 appropriations process - including HR 1 and various Continuing Resolutions

Issues related to pandemic preparedness and macular degeneration; HCR: Issues related to health care reform; FY11 FY12 Labor, HHS and Education Appropriation related to preparedness for pandemic influenza, HIV/AIDS programs and HCV screening, care and treatment. Implementation of HR 2346, S.1054 FY09 Supplemental Appropriations related to preparedness for pandemic influenza

Avastin, Lucentis, FDA, Appropriations; Issues concerning clinical trias. General health care reform (Patient Protection and Affordable Care Act). Congressional oversight issues; Legislation on public health preparedness and response to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels; FDA approval and enforcement issues; Prescription Drug User Fee Act (PDUFA), Avastin - use in breast cancer treatment, macular degeneration, S.726/HR 1427 - Promoting Innovation and Access to Life-Saving Medicine Act; HR 1548 - Pathway for Biosimilars Act, General support for Genentech products; HR1/1473 health care funding : FY 12 Labor HHS Appropriations legislation.

Avastin, Lucentis,FDA Appropriations; Issues concerning clincial trials. General health care reform (Patient Protection and Affordable Care Act). Congressional oversight issues; Legislation on public health preparedness and response to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels; FDA approval and enforcement issues; Presciption Drug User Fee Act (PDUFA), Avastin -use in breast cancer treatment, dry macular degeneration; S.726/HR 1427 - Promoting Innovation and Access to Life-Saving Medicine Act; HR 1548 - Pathway for Biosimilars Act, General support for Genentech products; HR1/1473 health care funding: FY 12 Labor HHS Appropriations legislation

Patent Settlement Issues; Intellectual Property and Process Patent Issues; H.R. 1908; S. 515 & HR. 1260 - Patent Reform Act of 2009; Monitor legislation regarding brand name and generic pharmaceutical agreement, patent fees, and post-grant review reforms.

H.R. 1908 Intellectual Property and Process Patent Issues S. 515 & H.R. 1260 - Patent Reform Act of 2009

S.515 & H.R. 1260 - Patent Reform Act of 2009

H.R. 1908 Intellectual Property and Process Patent Issues S. 515 & H.R. 1260 - Patent Reform Act of 2009

S. 515 & H.R. 1260 - Patent Reform Act of 2009

Physician payment disclosure including S.301 Physician Payments Sunshine Act of 2009 H.R. 3962, Affordable health Care for Americans Act H.R. 3590, Patient Protection and Affordable Care Act H.R. 4872, the Reconciliation Act of 2010 Follow-on biologics including H.R. 154, the Pathway to Biosimilars Act S. 726/H.R. 1427, Promoting Innovationo and Access to Life Saving Medicines Act H.R. 3962, Affordable Health Care for America Act Comparative effectiveness legislation including S. 1213 Patient-Centered Outcomes Research Act of 2009 H.R. 3200, America's Health Future Act H.R. 1548 - Pathway for Dissimilar Act Legislative changes in the health care reform bill regarding dissimilar Follow-on biolotics provisions in P.L. 111-148 "Patient protection and Affordable Care Act." Pandemic Preparedness - Tamiflu Exploring additional funding for antiviral stockpiling in response to H1N1 and H5N1 Pandemic Influenza H.R. 1105 - omnibus Appropriations Act FY10 labor HHS Appropriations Legislation H.R. 1105 - Omnibus Appropriations Act FY10 Labor HHS Appropriations legislation H.R. 2346 supplemental Appropriations Act of 2009 FY11 Labor, HHS and Education Appropriates related to preparedness for pandemic influenza, HIV/AIDS programs and HCV screening, care and treatment FY11 State Foreign Operations Appropriations related to USAID and funding for pandemic influenza H.R. 3974, Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009 Ryan White CARE Act reauthorization S. 1679, Affordable Health Choices Act S. 1796, America's Healthy Future Act of 2009 Pharmaceutical import safety legislation

Medicare issues; payment policies for prescription drugs; implementation of H.R.1; Medicare Prescription Drug and Modernization Act of 2003; Issues relating to PDUFA, stimulus; physician payment disclosure including S.301; Physician Payments Sunshine Act of 2009; HR 3962, Affordable Health Care for Americans Act; HR 3590, Patient Protection and Affordable Care Act; H.R.4872, the Reconciliation Act of 2010; Follow-on biologics including H.R. 154, the Pathway to Biosimilars Act; S726/H.R. 1427 Promoting innovation and access to Life Savings Medicines Act; HR 3962, Affordable Health Care for America Act; Compartiveffectiveness legislation S. 1213; Patient-Centered Outcomes Research Act of 2009; HR 3200, America's Health Future Act; H.R. 1548-Pathway for Dissimilar Act; Legislative changes in health care reform bill regarding dissimilar; Follow-on biolotics provisions in P.L. 111-148 "Patient protection and Affordable Care Act", Affordable Health Choice Act; American Health Future Act of 2009; Pharmaceutical Import Safety legislation.

Physician payment disclosure including S.301 Physician Payments Sunshine Act of 2009 H.R. 3962, Affordable health Care for Americans Act H.R. 3590, Patient Protection and Affordable Care Act H.R. 4872, the Reconciliation Act of 2010 Follow-on biologics including H.R. 154, the Pathway to Biosimilars Act S. 726/H.R. 1427, Promoting Innovationo and Access to Life Saving Medicines Act H.R. 3962, Affordable Health Care for America Act Comparative effectiveness legislation including S. 1213 Patient-Centered Outcomes Research Act of 2009 H.R. 3200, America's Health Future Act H.R. 1548 - Pathway for Dissimilar Act Legislative changes in the health care reform bill regarding dissimilar Follow-on biolotics provisions in P.L. 111-148 "Patient protection and Affordable Care Act." Pandemic Preparedness - Tamiflu Exploring additional funding for antiviral stockpiling in response to H1N1 and H5N1 Pandemic Influenza H.R. 1105 - omnibus Appropriations Act FY10 labor HHS Appropriations Legislation H.R. 1105 - Omnibus Appropriations Act FY10 Labor HHS Appropriations legislation H.R. 2346 supplemental Appropriations Act of 2009 FY11 Labor, HHS and Education Appropriates related to preparedness for pandemic influenza, HIV/AIDS programs and HCV screening, care and treatment FY11 State Foreign Operations Appropriations related to USAID and funding for pandemic influenza H.R. 3974, Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009 Ryan White CARE Act reauthorization S. 1679, Affordable Health Choices Act S. 1796, America's Healthy Future Act of 2009 Pharmaceutical import safety legislation

Pandemic Preparedeness: Tamiflu; Advocate on legislative changes in the health care reform bill regarding biosimilars; Monitor changes to outpatient 340B presecription drug discount program, including related provisions included in HR 4213 - American Jobs and Closing Tax Loopholes Act; S. 3793, Job Creation and TAx Cuts Act; All healthcare and biotechnology legislation. Stockpiling of antiviral in preparation of a pandemic, HHS Appropriations bill H.R. 1548 - Pathway for Biosimilars Act FDA Approval and Enforcement Issues Cancer Research Issues S. 3686 FY 2011 Appropriations, HHS HCR issues concerning clinical trials Congressional oversight issues Implementation issues related to the Patient Protection and Affordable Care Act H.R. 1 - Pandemic influenza funding H.R. 1105 Omnibus Appropriations Act, Pandemic Funding Issues Food Safety Bill, H.R. 4872 Health Care and Education Reconciliation Act of 2010 H.R. 3974 Viral Hepatitis and LIver Cancer Control and Prevention Act of 2009 H.R. 3590 Patient Projection and Affordable Care Act-FTC issue Ryan White CARE Act reauthorization S. 726/HR 1427 - Promoting Innovation and Access to Life-Saving Medicine Act Educational meetings in Senate with candiate for Patient Centered Outcomes Research Institute Board (PCORI)